Gilead Sciences, Inc. (BMV:GILD)

Market Cap	2.74T
Revenue (ttm)	533.52B
Net Income (ttm)	148.76B
Shares Out	n/a
EPS (ttm)	117.81
PE Ratio	18.39
Forward PE	14.55
Dividend	60.96 (2.68%)
Ex-Dividend Date	Sep 15, 2025

Volume	2,047
Average Volume	1,127
Open	2,209.25
Previous Close	2,276.40
Day's Range	2,208.00 - 2,209.25
52-Week Range	1,843.00 - 2,347.00
Beta	0.33
RSI	48.67
Earnings Date	Feb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: GILD

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD